[go: up one dir, main page]

WO2002058724A8 - Use of lp82 to treat body weight disorders - Google Patents

Use of lp82 to treat body weight disorders

Info

Publication number
WO2002058724A8
WO2002058724A8 PCT/US2002/000498 US0200498W WO02058724A8 WO 2002058724 A8 WO2002058724 A8 WO 2002058724A8 US 0200498 W US0200498 W US 0200498W WO 02058724 A8 WO02058724 A8 WO 02058724A8
Authority
WO
WIPO (PCT)
Prior art keywords
body weight
weight disorders
treat body
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000498
Other languages
French (fr)
Other versions
WO2002058724A3 (en
WO2002058724A2 (en
Inventor
Niles Wayne Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US10/466,695 priority Critical patent/US20040162237A1/en
Priority to EP02720768A priority patent/EP1390060A2/en
Publication of WO2002058724A2 publication Critical patent/WO2002058724A2/en
Anticipated expiration legal-status Critical
Publication of WO2002058724A3 publication Critical patent/WO2002058724A3/en
Publication of WO2002058724A8 publication Critical patent/WO2002058724A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

The present invention relates to a mammalian gene that is involved in the control of mammalian body weight. More specifically the present invention relates to methods of using compositions comprising LP82 polynucleotides, LP82 polypeptides, and/or LP82 antibodies for the prevention and/or treatment of mammalian body weight disorders, including obesity, cachexia, and anorexia.
PCT/US2002/000498 2001-01-26 2002-01-15 Use of lp82 to treat body weight disorders Ceased WO2002058724A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/466,695 US20040162237A1 (en) 2002-01-15 2002-01-15 Use of lp82 to treat body weight disorders
EP02720768A EP1390060A2 (en) 2001-01-26 2002-01-15 Use of lp82 to treat body weight disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26423901P 2001-01-26 2001-01-26
US60/264,239 2001-01-26

Publications (3)

Publication Number Publication Date
WO2002058724A2 WO2002058724A2 (en) 2002-08-01
WO2002058724A3 WO2002058724A3 (en) 2003-12-18
WO2002058724A8 true WO2002058724A8 (en) 2004-05-21

Family

ID=23005167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000498 Ceased WO2002058724A2 (en) 2001-01-26 2002-01-15 Use of lp82 to treat body weight disorders

Country Status (2)

Country Link
EP (1) EP1390060A2 (en)
WO (1) WO2002058724A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ES2267814T3 (en) 2000-09-15 2007-03-16 Zymogenetics, Inc. METHOD TO TREAT INFLAMMATION.
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
IL161978A0 (en) 2001-12-17 2005-11-20 Zymogenetics Inc Method for treating cervical cancer
MXPA05010134A (en) 2003-03-24 2005-11-16 Zymogenetics Inc Anti-il-20 antibodies and binding partners and methods of using in inflammation.
WO2005014028A1 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
JP4991307B2 (en) 2003-11-21 2012-08-01 ザイモジェネティクス， インコーポレイテッド Anti-IL-20 antibodies and binding partners and methods for use in inflammation
US7537761B2 (en) 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CN1618969A (en) * 1997-11-26 2005-05-25 津莫吉尼蒂克斯公司 Mammalian sytokine-like polypeptide-10

Also Published As

Publication number Publication date
WO2002058724A3 (en) 2003-12-18
WO2002058724A2 (en) 2002-08-01
EP1390060A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2001083729A3 (en) Vectors for ocular transduction and use thereof for genetic therapy
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1038755A1 (en) Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
WO2004032877A3 (en) Compositions, organisms and methodologies employing a novel human kinase
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2002058724A3 (en) Use of lp82 to treat body weight disorders
WO2003033557A3 (en) Copolymers containing fluorine, method for the production and use thereof
WO1999051727A3 (en) Human nucleic acid sequences of normal ovary tissue
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
WO2005112903A3 (en) Use of ghrelin antagonists for improving cognition and memory
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2004091646A3 (en) Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
WO2006028492A3 (en) hC1Q/TNF7 AND USES THEREOF
WO2002060382A3 (en) Novel compounds and uses thereof
EP1440080A4 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AU2002365621A1 (en) Composition for treating the surface of the skin
WO2003033534A3 (en) Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
ZA200302911B (en) Method and composition for treatment of ocular hypertension and glaucoma.
IL159081A0 (en) Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
AU2003290560A1 (en) Inmould process for the spheroidization and inoculation treatment of cast sg iron

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10466695

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002720768

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002720768

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWW Wipo information: withdrawn in national office

Ref document number: 2002720768

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP